5-甲基-2-吡啶羰酰氯(9ci) | 128073-07-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-甲基-2-吡啶羰酰氯(9ci)
• 英文名称: 5-methylpicolinoyl chloride
• 英文别名: 5-Methylpyridine-2-carbonyl chloride
• CAS: 128073-07-4
• 化学式: C₇H₆ClNO
• 分子量: 155.584
• InChiKey: FGQHLHAEBIAFPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-甲基-2-吡啶羰酰氯(9ci) 在 盐酸 、 铁粉 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 17.25h， 生成 5-methyl-2-(1-methylbenzimidazol-2-yl)pyridine
  参考文献：
  名称：

  A Comparison of the Lability of Mononuclear Octahedral and Dinuclear Triple-Helical Complexes of Cobalt(II)

  摘要：

  The lability of the mononuclear octahedral complex tris(5-methyl-2-(1'-methylbenzimidazol-2-yl)-pyridine)-cobalt(II), [Co(2)(3)](2+), is compared with the dinuclear triple-helical complex tris[bis[1-methyl-2-(5'-methylpyrid-2'-yl]benzimidazol-5-yl]methane]dicobalt(II), [Co-2(1a)(3)](4+).[Co(2)(3)](2+) undergoes rapid isomerization between mer and fac forms (k(298)(mer-fac) = 1.6 +/- 0.2 s(-1)) in acetonitrile while the racemization of (-)(589)-[Co-2(1a)(3)](4+) is roughly 10(5) times slower (k(298) = 1.4 +/- 2 10(-5) s(-1)). The pressure dependence of the isomerization of [Co(2)(3)](2+) suggests a dissociatively activated process. The racemization of (-)(589)-[Co-2(1a)(3)](4+) is found to be independent of pH above pH 4, and is not affected by added cobalt(II) or a change of solvent. Ligand exchange between [Co-2(1b)(3)](4+) (1b = bis[1-ethyl-2-(5'-methylpyrid-2'-yl)benzimidazol-5-yl]methane) and free la may be followed by electrospray mass spectrocopy and establishes the mechanism of formation of the triple helix to be initial formation of mononuclear [Co(1a)(3)](2+) followed by capping by a second cobalt to give [Co-2(1a)(3)](4+). The slow racemization of (-)(589)-[Co-2-(1a)(3)](4+) is attributed to the very slow dissociation of a cobalt ion from the triple helix: This inertness is attributed to the rigidity of the ligand and the tight pitch of the helix.

  DOI：

  10.1021/ja963693l
• 作为产物：
  描述：

  2,5-二甲基吡啶 在 selenium(IV) oxide 作用下， 以 吡啶 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 52.75h， 生成 5-甲基-2-吡啶羰酰氯(9ci)
  参考文献：
  名称：

  Smaller than a nanoparticle with the design of discrete polynuclear molecular complexes displaying near-infrared to visible upconversion

  摘要：

  一种前所未有的分子[ErN₉]色素团在间接激发下同时发射双绿光(542纳米)和近红外光(1540纳米)。

  DOI：

  10.1039/c4dt02336f

文献信息

• NEW BIS-AMIDO PYRIDINES
  申请人：REISER Ulrich

  公开号：US20150057286A1

  公开（公告）日：2015-02-26

  This invention relates to bis-amido pyridines of general formula (I) their use as SMAC mimetics, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R 1 to R 4 have the meanings given in the claims and in the specification.

  这项发明涉及一般式（I）的双酰胺吡啶，其作为SMAC模拟物的用途，含有它们的药物组合物，以及它们作为治疗和/或预防由细胞过度或异常增殖引起的疾病及相关症状（如癌症）的药物的用途。R1至R4基团的含义如索赔和说明书中所述。
• [EN] NEW BIS-AMIDO PYRIDINES<br/>[FR] NOUVEAUX BIS-AMIDO PYRIDINES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2015025018A1

  公开（公告）日：2015-02-26

  This invention relates to bis-amidopyridinesof general formula (I) their use as SMAC mimetics, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R1 to R4 have the meanings given in the claims and in the specification.

  这项发明涉及一般式（I）的双酰胺吡啶类化合物，它们作为SMAC模拟物的用途，含有它们的药物组合物，以及它们作为治疗和/或预防由细胞过度或异常增殖引起的疾病及相关症状（如癌症）的药物的用途。基团R1到R4的含义如权利要求和说明书中所述。
• Design, synthesis and biological activity evaluation of a new class of 2,4-thiazolidinedione compounds as insulin enhancers
  作者：Zou Huiying、Chen Guangying、Zhou Shiyang

  DOI：10.1080/14756366.2019.1608197

  日期：2019.1.1

  Rosiglitazone was taken as the lead compound, and the structure was modified by using the bioisostere principle, and a new class of 2,4-thiazolanedione compound was designed and synthesised. The novel series of compounds were studied for their biological activities in vitro and in vivo. In vitro tests, the biological activities showed that the target compounds have good selective activation of pe

  抽象的 糖尿病（DM）是一种全球性疾病，2型糖尿病的发生率很高。当前的研究表明，胰岛素增强剂在2型糖尿病的治疗中起着重要的作用，并且在2型糖尿病的改善中具有重要的意义。本研究以罗格列酮为主要化合物，利用生物等排体原理对结构进行了修饰，设计并合成了一种新型的2,4-噻唑二酮化合物。研究了该系列新化合物的体外和体内生物学活性。在体外试验中，生物学活性表明目标化合物具有良好的选择性过氧化物酶体增殖物激活受体γ（PPARγ）的激活能力，例如化合物6a，图6e，图6f，6克和6i的，尤其是化合物6E到PPARγ为EC 50  = 0.03±0.01微摩尔/ L的体外。然后，体内生物活性的测试结果表明，血糖升高的趋势具有明显的抑制作用，并且具有增强和扩展外源性胰岛素的显着的降血糖作用。另外，细胞毒性试验和急性毒性试验的结果（LD 50）表明这些化合物属于低毒性化合物。
• [EN] VIRAL POLYMERASE INHIBITORS<br/>[FR] INHIBITEURS DE POLYMÉRASE VIRALE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009076747A1

  公开（公告）日：2009-06-25

  Compounds of formula I: wherein X, R2, R3, R3a, R3b,R5 and R6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.

  式I的化合物：其中X，R2，R3，R3a，R3b，R5和R6在此处定义，可用作乙型肝炎病毒NS5B聚合酶的抑制剂。
• Pyridinecarboxylic acid amide derivatives and pharmaceutical
  申请人：Nisshin Flour Milling Co., Ltd.

  公开号：US05250526A1

  公开（公告）日：1993-10-05

  Compounds are disclosed of the formula ##STR1## wherein R.sub.1 is hydrogen, C.sub.1 -C.sub.3 alkyl or diphenylmethyl; Y is --NH(CH.sub.2).sub.n --R.sub.2 ; R.sub.2 is OH or --ONO.sub.2 ; m is 2 or 3; and n is 9 to 13 or physiologically acceptable acid addition salts thereof. The compounds of formula (I) are of a blood flow-increasing and hypotensive actions and can be used for the therapy or prevention of diseases in the cardiovascular system.

  公式为##STR1##的化合物已被披露，其中R.sub.1为氢、C.sub.1 -C.sub.3烷基或二苯甲基；Y为--NH(CH.sub.2).sub.n --R.sub.2；R.sub.2为OH或--ONO.sub.2；m为2或3；n为9至13或其生理上可接受的酸盐。公式（I）的化合物具有增加血流和降压作用，可用于治疗或预防心血管系统疾病。